ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer
- PMID: 27964905
- DOI: 10.1016/j.brachy.2016.10.002
ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer
Abstract
Purpose: To provide updated American College of Radiology (ACR) appropriateness criteria for transrectal ultrasound-guided transperineal interstitial permanent source brachytherapy.
Methods and materials: The ACR appropriateness criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
Results: Permanent prostate brachytherapy (PPB) is a treatment option for appropriately selected patients with localized prostate cancer with low to very high risk disease. PPB monotherapy remains an appropriate and effective curative treatment for low-risk prostate cancer patients demonstrating excellent long-term cancer control and acceptable morbidity. PPB monotherapy can be considered for select intermediate-risk patients with multiparametric MRI useful in evaluation of such patients. High-risk patients treated with PPB should receive supplemental external beam radiotherapy (EBRT) along with androgen deprivation. Similarly, patients with involved pelvic lymph nodes may also be considered for such combined treatment but reported long-term outcomes are limited. Computed tomography-based postimplant dosimetry completed within 60 days of PPB is essential for quality assurance. PPB may be considered for treatment of local recurrence after EBRT but is associated with an increased risk of toxicity.
Conclusions: Updated appropriateness criteria for patient evaluation, selection, treatment, and postimplant dosimetry are given. These criteria are intended to be advisory only with the final responsibility for patient care residing with the treating clinicians.
Keywords: Brachytherapy; Guideline; Prostate cancer; Radiation therapy; Radiotherapy; Standard.
Copyright © 2016 The American College of Radiology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy.Brachytherapy. 2012 Jan-Feb;11(1):6-19. doi: 10.1016/j.brachy.2011.07.005. Brachytherapy. 2012. PMID: 22265434
-
ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer.Brachytherapy. 2014 Jan-Feb;13(1):27-31. doi: 10.1016/j.brachy.2013.11.007. Epub 2013 Dec 22. Brachytherapy. 2014. PMID: 24368283 Review.
-
American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer.Brachytherapy. 2011 Sep-Oct;10(5):357-62. doi: 10.1016/j.brachy.2011.01.014. Epub 2011 Apr 16. Brachytherapy. 2011. PMID: 21497562 Review.
-
ACR Appropriateness Criteria® definitive external beam irradiation in stage T1 and T2 prostate cancer.Am J Clin Oncol. 2011 Dec;34(6):636-47. doi: 10.1097/COC.0b013e3182354a65. Am J Clin Oncol. 2011. PMID: 22101389 Review.
-
ACR Appropriateness Criteria® Definitive External-Beam Irradiation in stage T1 and T2 prostate cancer.Am J Clin Oncol. 2014 Jun;37(3):278-88. doi: 10.1097/COC.0000000000000049. Am J Clin Oncol. 2014. PMID: 25180754 Review.
Cited by
-
A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes.J Contemp Brachytherapy. 2018 Apr;10(2):155-161. doi: 10.5114/jcb.2018.75600. Epub 2018 Apr 30. J Contemp Brachytherapy. 2018. PMID: 29789764 Free PMC article. Review.
-
A Younger Man With Localized Prostate Cancer Asks, "Which Type of Radiation Is Right for Me?".J Clin Oncol. 2018 Jun 20;36(18):1780-1784. doi: 10.1200/JCO.2018.77.7235. Epub 2018 May 2. J Clin Oncol. 2018. PMID: 29718792 Free PMC article.
-
Is intraoperative real-time dosimetry in prostate seed brachytherapy predictive of biochemical outcome?J Contemp Brachytherapy. 2017 Aug;9(4):304-308. doi: 10.5114/jcb.2017.68467. Epub 2017 Jun 22. J Contemp Brachytherapy. 2017. PMID: 28951748 Free PMC article.
-
Low dose rate prostate brachytherapy.Transl Androl Urol. 2018 Jun;7(3):341-356. doi: 10.21037/tau.2017.12.15. Transl Androl Urol. 2018. PMID: 30050795 Free PMC article. Review.
-
Characteristics and risk differences of different tumor size on localized prostate cancer: A retrospective cohort study in the SEER database.Cancer Med. 2021 Apr;10(8):2763-2773. doi: 10.1002/cam4.3856. Epub 2021 Mar 16. Cancer Med. 2021. PMID: 33724697 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical